---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-001602"
form_type: "8-K"
ticker: "CFOR"
cik: "0001293818"
company_name: "CapForce Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:14:54.894298+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# OpGen Q3 revenue $0.7M; subsidiaries Curetis & Ares Genetics file insolvency, going concern doubt

## Summary
- Total revenue Q3 2023 $0.70M vs $0.45M; nine-month $2.35M vs $1.89M.
- Cash and equivalents $0.29M at Sep 30; subsequent financing raised ~$3.06M but substantial doubt about going concern.
- Subsidiaries Curetis GmbH and Ares Genetics GmbH filed for insolvency Nov 6, 2023 under German/Austrian laws.
- OpGen reduced U.S. headcount from 23 to 6; discontinued Acuitas AMR Gene Panel test.
- Total operating expenses Q3 2023 $4.26M vs $13.96M (incl. $6.98M goodwill impairment in prior year).

## SEC filing metadata
- accession: 0001079973-23-001602
- form_type: 8-K
- ticker: CFOR
- cik: 0001293818
- company_name: CapForce Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/0001079973-23-001602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/opgen_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-001602
- JSON: https://secwatch.observer/filing/0001079973-23-001602.json
- Plain text: https://secwatch.observer/filing/0001079973-23-001602.txt

## Key facts
- Earnings Releases
  CapForce Inc. reported third quarter 2023 results: revenue approximately $0.70 million.
  - Period: third quarter 2023
  - Revenue: approximately $0.70 million
  - Result: reported results
  source text: its third quarter 2023 financial and operating results. Third Quarter 2023 Financial Results of OpGen, Inc. · Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022. Total revenue for the nine months ended September 30, 2023 was approximately $2.35
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/0001079973-23-001602-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.